nach oben

Endocrine

Erschienen in:

28.06.2022 | Review

Autoimmune and inflammatory thyroid diseases following vaccination with SARS-CoV-2 vaccines: from etiopathogenesis to clinical management

verfasst von: Philippe Caron

Erschienen in: Endocrine | Ausgabe 3/2022

Einloggen, um Zugang zu erhalten

Abstract

Since the Covid-19 pandemic emerged in 2019, several adenoviral-vectored, mRNA-based and inactivated whole-virus vaccines have been developed. A massive vaccination campaign has been undertaken around the world, and an increasing number of SARS-CoV-2 vaccine-induced thyroid diseases have been described in the literature. Subacute thyroiditis has been reported in 52 patients, mean age 45.5 ± 1.8 years, mainly in women (n = 39). Graves’ disease is more frequent in women (n = 22) than in men (n = 10), mean age 46.2 ± 2.6 years, reported as new onset, recurrent or exacerbation of well-controlled hyperthyroidism. The mean time to symptoms onset is 9.0 ± 0.8 days in subacute thyroiditis, and 15.1 ± 2.6 days in Graves’ patients. Rare patients (n = 6) present silent or painless autoimmune thyroiditis. Thyroid function and autoimmune tests, inflammatory markers, thyroid echography with colour flow Doppler, radio-activity uptake on thyroid scan, medical treatment and follow-up are described and compared in patients with SARS-CoV-2 vaccine-induced thyroid diseases. The underlying pathogenic mechanisms of vaccine-induced thyroid diseases, molecular mimicry (various SARS-CoV-2 proteins sharing a genetic homology with a large heptapeptide human protein) or autoimmune/inflammatory syndrome induced by adjuvants (ASIA) are discussed in the context of predisposition or genetic susceptibility. The benefits of SARS-CoV-2 vaccination far outweigh the potential vaccine-induced adverse effects, but clinicians should be aware of possible autoimmune and inflammatory thyroid diseases, and can advise patients to seek medical assistance when experiencing anterior neck pain, fever or palpitations following SARS-CoV-2 vaccines. Further studies are warranted to investigate the etiopathogenesis and to clarify the factors which predispose patients to SARS-CoV-2 vaccine-induced thyroid diseases.

B.G. İremli, S.N. Şendur, U. Ünlütürk, Three cases of subacute thyroiditis following SARS-CoV-2 vaccine: postvaccination ASIA syndrome. J. Clin. Endocrinol. Metab. 106(9), 2600–2605 (2021). https://doi.org/10.1210/clinem/dgab373CrossRefPubMed

S.O. Oyibo, Subacute thyroiditis after receiving the adenovirus-vectored vaccine for coronavirus disease (COVID-19). Cureus 13, e16045 (2021). https://doi.org/10.7759/cureus.16045CrossRefPubMedPubMedCentral

S. Franquemont, J. Juan Galvez, Subacute thyroiditis after mRNA vaccine for Covid‐19. J. Endocr. Soc. 5, A956–A957 (2021). https://doi.org/10.1210/jendso/bvab048.1954CrossRefPubMedCentral

J. Schimmel, E.L. Alba, A. Chen, M. Russell, R. Srinath, Letter to the Editor: thyroiditis and thyrotoxicosis after the SARS-CoV-2 mRNA vaccine. Thyroid 31, 1440 (2021). https://doi.org/10.1089/thy.2021.0184CrossRefPubMed

E.S. Saygılı, E. Karakilic, Subacute thyroiditis after inactive SARS-CoV-2 vaccine. BMJ Case Rep. 14, e244711 (2021). https://doi.org/10.1136/bcr-2021-244711CrossRefPubMedPubMedCentral

E. Sigstad, K.K. Grøholt, O. Westerheim, Subacute thyroiditis after vaccination against SARS-CoV-2. Tidsskr Nor Laegeforen. 2021, 141 (2021-14). https://doi.org/10.4045/tidsskr.21.0554

M.S. Jeeyavudeen, A.W. Patrick, F.W. Gibb, A.R. Dover, COVID-19 vaccine-associated subacute thyroiditis: an unusual suspect for de Quervain’s thyroiditis. BMJ Case Rep. 14, e246425 (2021). https://doi.org/10.1136/bcr-2021-246425CrossRefPubMedPubMedCentral

P. Soltanpoor, G. Norouzi, Subacute thyroiditis following COVID-19 vaccination. Clin. Case Rep. 9, e04812 (2021). https://doi.org/10.1002/ccr3.4812CrossRefPubMedPubMedCentral

G.M. Ratnayake, D. Dworakowska, A.B. Grossman, Can COVID-19 immunisation cause subacute thyroiditis? Clin. Endocrinol. (2021). https://doi.org/10.1111/cen.14555

10.

M. Sözen, Ö. Topaloğlu, B. Çetinarslan, A. Selek, Z. Cantürk, E. Gezer, D. Köksalan, T. Bayraktaroğlu, COVID-19 mRNA vaccine may trigger subacute thyroiditis. Hum. Vaccin. Immunother. 1–6 (2021). https://doi.org/10.1080/21645515.2021.2013083

11.

A. Kyriacou, S. Ioakim, A.A. Syed, COVID-19 vaccination and a severe pain in the neck. Eur. J. Intern. Med. 94, 95–96 (2021). https://doi.org/10.1016/j.ejim.2021.10.008

12.

K.R. Patel, M.E. Cunnane, D.G. Deschler, SARS-CoV-2 vaccine-induced subacute thyroiditis. Am. J. Otolaryngol. 43, 103211 (2022). https://doi.org/10.1016/j.amjoto.2021.103211CrossRefPubMed

13.

M. Şahin Tekin, S. Şaylısoy, G. Yorulmaz, Subacute thyroiditis following COVID-19 vaccination in a 67-year-old male patient: a case report. Hum. Vaccin Immunother. 17, 4090–4092 (2021). https://doi.org/10.1080/21645515.2021.1947102CrossRefPubMedPubMedCentral

14.

C. Bornemann, K. Woyk, C. Bouter, Case report: two cases of subacute thyroiditis following SARS-CoV-2 vaccination. Front Med. 8, 737142 (2021). https://doi.org/10.3389/fmed.2021.737142CrossRef

15.

K.A. Lee, Y.J. Kim, H.Y. Jin, Thyrotoxicosis after COVID-19 vaccination: seven case reports and a literature review. Endocrine 74, 470–472 (2021). https://doi.org/10.1007/s12020-021-02898-5CrossRefPubMedPubMedCentral

16.

A. Siolos, K. Gartzonika, S. Tigas. Metabol Open. Thyroiditis following vaccination against COVID-19: Report of two cases and review of the literature. Metab. Open 12, 100136 (2021). https://doi.org/10.1016/j.metop.2021.100136

17.

A. Pujol, L.A. Gómez, C. Gallegos, J. Nicolau, P. Sanchís, M. González-Freire, Á.A. López-González, K. Dotres, L. Masmiquel, Thyroid as a target of adjuvant autoimmunity/inflammatory syndrome due to mRNA-based SARS-CoV2 vaccination: from Graves’ disease to silent thyroiditis. J. Endocrinol. Invest. 1–8 (2021). https://doi.org/10.1007/s40618-021-01707-0

18.

M. Pandya, G. Thota, X. Wang, H. Luo. Thyroiditis after coronavirus disease 2019 (COVID-19) mRNA vaccine: a case series. AACE Clin. Case Rep. (2021). https://doi.org/10.1016/j.aace.2021.12.002

19.

B. Pla Peris, A.Á. Merchante Alfaro, F.J. Maravall Royo, P. Abellán Galiana, S. Pérez Naranjo, M. González Boillos, Thyrotoxicosis following SARS-COV-2 vaccination: a case series and discussion. J Endocrinol. Invest. 1–7 (2022). https://doi.org/10.1007/s40618-022-01739-0

20.

L. Das, S.K. Bhadada, A. Sood, Post-COVID-vaccine autoimmune/inflammatory syndrome in response to adjuvants (ASIA syndrome) manifesting as subacute thyroiditis. J. Endocrinol. Invest. 45, 465–467 (2022). https://doi.org/10.1007/s40618-021-01681-7CrossRefPubMed

21.

L.M. Raven, A.I. McCormack, J.R. Greenfield, Letter to the Editor from Raven: three cases of subacute thyroiditis following SARS-CoV-2 vaccine. J Clin Endocrinol Metab. dgab822 (2021). https://doi.org/10.1210/clinem/dgab822.

22.

S. Chatzi, A. Karampela, C. Spiliopoulou, G. Boutzios, Subacute thyroiditis after SARS-CoV-2 vaccination: a report of two sisters and summary of the literature. Hormones 21, 177–179 (2022). https://doi.org/10.1007/s42000-021-00332-z.CrossRefPubMed

23.

S.H. Oğuz, S.N. Şendur, B.G. İremli, A. Gürlek, T. Erbas, U. Ünlütürk, SARS-CoV-2 vaccine-induced thyroiditis: safety of Re-vaccinations and Clinical Follow-up. J. Clin. Endocrinol. Metab. dgac049 (2022). https://doi.org/10.1210/clinem/dgac049

24.

O. Vera-Lastra, A. Ordinola Navarro, M.P. Cruz Domiguez, G. Medina, T.I. Sánchez Valadez, L.J. Jara, Two cases of Graves’ disease following SARS-CoV-2 vaccination: an autoimmune/inflammatory syndrome induced by adjuvants. Thyroid 31, 1436–1439 (2021). https://doi.org/10.1089/thy.2021.0142CrossRefPubMed

25.

G. Zettinig, M. Krebs, Two further cases of Graves’ disease following SARS-Cov-2 vaccination. J. Endocrinol. Invest. 45, 227–228 (2022). https://doi.org/10.1007/s40618-021-01650-0CrossRefPubMed

26.

C. Sriphrapradang, P.C. Shantavasinkul, Graves’ disease following SARS-CoV-2 vaccination. Endocrine 74, 473–474 (2021). https://doi.org/10.1007/s12020-021-02902-yCrossRefPubMedPubMedCentral

27.

T.J. Goblirsch, A.E. Paulson, G. Tashko, A.J. Mekonnen, Graves’ disease following administration of second dose of SARS-CoV-2 vaccine. BMJ Case Rep. 14, e246432 (2021). https://doi.org/10.1136/bcr-2021-246432CrossRefPubMedPubMedCentral

28.

W. Hamouche, Y. El Soufi, S. Alzaraq, B.V. Okafor, F. Zhang, C. Paras, A case report of new onset graves’ disease induced by SARS-CoV-2 infection or vaccine? J. Clin. Transl. Endocrinol. Case Rep. 23, 100104 (2022). https://doi.org/10.1016/j.jecr.2021.100104CrossRefPubMed

29.

D.T.W. Lui, K.K. Lee, C.H. Lee, A.C.H. Lee, I.F.N. Hung, K.C.B. Tan, Development of Graves’ disease after SARS-CoV-2 mRNA vaccination: a case report and literature review. Front. Public Health 9, 778964 (2021). https://doi.org/10.3389/fpubh.2021.778964CrossRefPubMedPubMedCentral

30.

A. Patrizio, S.M. Ferrari, A. Antonelli, P. Fallahi, A case of Graves’ disease and type 1 diabetes mellitus following SARS-CoV-2 vaccination. J. Autoimmun. 125, 102738 (2021). https://doi.org/10.1016/j.jaut.2021.102738CrossRefPubMedPubMedCentral

31.

C. Sriphrapradang, Aggravation of hyperthyroidism after heterologous prime-boost immunization with inactivated and adenovirus-vectored SARS-CoV-2 vaccine in a patient with Graves’ disease. Endocrine 74, 226–227 (2021). https://doi.org/10.1007/s12020-021-02879-8.CrossRefPubMedPubMedCentral

32.

G. Pierman, E. Delgrange, C. Jonas, Recurrence of Graves’ disease (a Th1-type Cytokine Disease) following SARS-CoV-2 mRNA vaccine administration: a simple coincidence? Eur. J. Case Rep. Intern Med. 8, 002807 (2021). https://doi.org/10.12890/2021_002807CrossRefPubMedPubMedCentral

33.

K. Yamamoto, T. Mashiba, K. Takano, T. Suzuki, M. Kami, M. Takita, E. Kusumi, Y. Mizuno, T. Hamaki, A case of exacerbation of subclinical hyperthyroidism after first administration of BNT162b2 mRNA COVID-19 vaccine. Vaccines 9, 1108 (2021). https://doi.org/10.3390/vaccines9101108CrossRefPubMedPubMedCentral

34.

L. di Filippo, L. Castellino, A. Giustina, Occurrence and response to treatment of Graves’ disease after COVID vaccination in two male patients. Endocrine 75, 19–21 (2022). https://doi.org/10.1007/s12020-021-02919-3.CrossRefPubMed

35.

M.A. Weintraub, B. Ameer, N. Sinha Gregory, Graves disease following the SARS-CoV-2 vaccine: case series. J. Investig. Med. High. Impact Case Rep. 9, 23247096211063356 (2021). https://doi.org/10.1177/23247096211063356CrossRefPubMedPubMedCentral

36.

H.M. Leber, L. Sant’Ana, N.R. Konichi da Silva, M.C. Raio, T.J.M.M. Mazzeo, C.M. Endo, H. Nascimento, C.E. de Souza, Acute thyroiditis and bilateral optic neuritis following SARS-CoV-2 vaccination with CoronaVac: a case report. Ocul. Immunol. Inflamm. 29, 1200–1206 (2021). https://doi.org/10.1080/09273948.2021.1961815CrossRefPubMed

37.

M. Capezzone, M. Tosti-Balducci, E.M. Morabito, G.P. Caldarelli, A. Sagnella, S. Cantara, M. Alessandri, M.G. Castagna, Silent thyroiditis following vaccination against COVID-19: report of two cases. J Endocrinol Invest. 1–5, (2022). https://doi.org/10.1007/s40618-021-01725-y

38.

L. Mukhopadhyay, P.D. Yadav, N. Gupta, S. Mohandas, D.Y. Patil, A. Shete-Aich, S. Panda, B. Bhargava, Comparison of the immunogenicity & protective efficacy of various SARS-CoV-2 vaccine candidates in non-human primates. Indian J. Med. Res. 153, 93–114 (2021). https://doi.org/10.4103/ijmr.IJMR_4431_20CrossRefPubMedPubMedCentral

39.

Y.H. Chin, C.H. Ng, M.H. Lee, J.W.H. Koh, J. Kiew, S.P. Yang et al. Prevalence of thyroid eye disease in Graves’ disease: a meta-analysis and systematic review. Clin. Endocrinol. 93(4), 363–74 (2020)CrossRef

40.

T.J. Rubinstein, Thyroid Eye Disease Following COVID-19 vaccine in a patient with a history Graves’ disease: a case report. Ophthalmic Plast. Reconstr. Surg. 37, e221–e223 (2021). https://doi.org/10.1097/IOP.0000000000002059CrossRefPubMedPubMedCentral

41.

F. Fang, S. Yan, L. Zhao, Y. Jin, Y. Wang, Concurrent onset of subacute thyroiditis and Graves׳ disease. Am. J. Med Sci. 352, 224–6 (2016). https://doi.org/10.1016/j.amjms.2016.04.009CrossRefPubMed

42.

T.D. Hoang, V.Q. Mai, P.W. Clyde, M.K. Shakir, Simultaneous occurrence of subacute thyroiditis and Graves’ disease. Thyroid 21, 1397–400 (2011). https://doi.org/10.1089/thy.2011.0254CrossRefPubMed

43.

A. Vojdani, E. Vojdani, D. Kharrazian, Reaction of human monoclonal antibodies to SARS-CoV-2 proteins with tissue antigens: implications for autoimmune diseases. Front Immunol. 11, 617089 (2021). https://doi.org/10.3389/fimmu.2020.617089CrossRefPubMedPubMedCentral

44.

Y. Shoenfeld, N. Agmon-Levin, ‘ASIA’ - autoimmune/inflammatory syndrome induced by adjuvants. J. Autoimmun. 36, 4–8 (2011). https://doi.org/10.1016/j.jaut.2010.07.003CrossRefPubMed

45.

N.L. Bragazzi, A. Hejly, A. Watad, M. Adawi, H. Amital, Y. Shoenfeld, ASIA syndrome and endocrine autoimmune disorders. Best. Pr. Res Clin. Endocrinol. Metab. 34, 101412 (2020). https://doi.org/10.1016/j.beem.2020.101412.CrossRef

46.

A. Passah, S. Arora, N.A. Damle, K.S. Reddy, D. Khandelwal, S. Aggarwal, Occurrence of subacute thyroiditis following influenza vaccination. Indian J. Endocrinol. Metab. 22, 713–714 (2018). https://doi.org/10.4103/ijem.IJEM_237_18CrossRefPubMedPubMedCentral

47.

J.Y. Hsiao, S.C. Hsin, M.C. Hsieh, P.J. Hsia, S.J. Shin, Subacute thyroiditis following influenza vaccine (Vaxigrip) in a young female. Kaohsiung J. Med. Sci. 22, 297–300 (2006). https://doi.org/10.1016/s1607-551x(09)70315-8CrossRefPubMed

48.

C.M. Girgis, R.R. Russo, K. Benson, Subacute thyroiditis following the H1N1 vaccine. J. Endocrinol. Invest. 33, 506 (2010). https://doi.org/10.1007/BF03346633CrossRefPubMed

49.

J. Toft, S. Larsen, H. Toft, Subacute thyroiditis after hepatitis B vaccination. Endocr. J. 45, 135 (1998)PubMed

50.

P. Pellegrino, V. Perrone, M. Pozzi, C. Carnovale, C. Perrotta, E. Clementi, S. Radice, The epidemiological profile of ASIA syndrome after HPV vaccination: an evaluation based on the Vaccine Adverse Event Reporting Systems. Immunol. Res. 61, 90–6 (2015). https://doi.org/10.1007/s12026-014-8567-3CrossRefPubMed

51.

T.J. Smith, L. Hegedüs, Graves’ disease. N. Engl. J. Med. 375, 1552–1565 (2016)CrossRefPubMed

52.

T.F. Davies, S. Andersen, R. Latif, Y. Nagayama, G. Barbesino, M. Brito, A.K. Eckstein, A. Stagnaro-Green, G.J. Kahaly, Graves’ disease. Nat. Rev. Dis. Prim. 6, 52 (2020). https://doi.org/10.1038/s41572-020-0184-yCrossRefPubMed

53.

M. Stasiak, B. Tymoniuk, R. Michalak, B. Stasiak, M.L. Kowalski, A. Lewiński, Subacute thyroiditis is associated with HLA-B*18:01, -DRB1*01 and -C*04:01-the significance of the new molecular background. J. Clin. Med. 9, 534 (2020). https://doi.org/10.3390/jcm9020534CrossRefPubMedCentral

Titel: Autoimmune and inflammatory thyroid diseases following vaccination with SARS-CoV-2 vaccines: from etiopathogenesis to clinical management
verfasst von: Philippe Caron
Publikationsdatum: 28.06.2022
Verlag: Springer US
Erschienen in: Endocrine / Ausgabe 3/2022
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI: https://doi.org/10.1007/s12020-022-03118-4

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Aquatherapie bei Fibromyalgie wirksamer als Trockenübungen

03.05.2024 Fibromyalgiesyndrom Nachrichten

Bewegungs-, Dehnungs- und Entspannungsübungen im Wasser lindern die Beschwerden von Patientinnen mit Fibromyalgie besser als das Üben auf trockenem Land. Das geht aus einer spanisch-brasilianischen Vergleichsstudie hervor.

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Das Risiko für Vorhofflimmern in der Bevölkerung steigt

02.05.2024 Vorhofflimmern Nachrichten

Das Risiko, im Lauf des Lebens an Vorhofflimmern zu erkranken, ist in den vergangenen 20 Jahren gestiegen: Laut dänischen Zahlen wird es drei von zehn Personen treffen. Das hat Folgen weit über die Schlaganfallgefährdung hinaus.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2022

Sorafenib decreases glycemia by impairing hepatic glucose metabolism

Pre- and peri-operative characteristics, complications and outcomes of patients with biochemically silent pheochromocytomas; a case series

Incomplete response to therapy in intermediate- and high-risk thyroid cancer

The combination of BRAFV600E mutation and Chinese Thyroid Imaging Reporting and Data System is helpful in the management of AUS/FLUS thyroid nodules

Prognostic significance of lung metastasis-related finding in lenvatinib treatment for differentiated thyroid cancer